Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer

Table 2 Multivariable analyses in the exploration HRPBC cohort

Covariates	Recurrence-free survival		Breast cancer-specific survival
Covariates	HR (95% CI)	P	HR (95% CI)	P
FFAR4 (continuous)	1.058 (1.029–1.088)	< 0.001	1.052 (1.018–1.088)	0.003
Age at diagnosis	0.988 (0.968–1.009)	0.260	0.999 (0.974–1.024)	0.907
Grade (3 vs 2 or 1)	1.684 (1.068–2.655)	0.025	1.070 (0.611–1.877)	0.812
Tumor size (> 2 cm vs ≤ 2 cm)	0.886 (0.553–1.419)	0.614	1.391 (0.775–2.499)	0.269
LN (positive vs negative)	3.331 (2.015–5.505)	< 0.001	2.873 (1.566–5.270)	0.001
FFAR4 (high vs low)	2.183 (1.360–3.504)	0.001	2.102 (1.173–3.766)	0.013
Age at diagnosis	0.987 (0.966–1.008)	0.209	0.999 (0.974–1.024)	0.940
Grade (3 vs 2 or 1)	1.777 (1.136–2.780)	0.012	1.122 (0.646–1.950)	0.682
Tumor size (> 2 cm vs ≤ 2 cm)	0.934 (0.585–1.491)	0.776	1.418 (0.791–2.541)	0.241
LN (positive vs negative)	3.011 (1.840–4.929)	< 0.001	2.644 (1.454–4.808)	0.001

Abbrevation: LN Lymph node status, HR hazard ratio, CI confidence interval
FFAR4 H-score as a continuous variable (0 to 300, increment in every 10 point) or as a binary variable (high vs low). Age in years as a continuous variable. All Wald statistical tests were two-sided; boldface was used to indicate the key variable (FFAR4)

ISSN: 1756-9966